{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:49:56Z","timestamp":1792172996251,"version":"4.4.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pilot Feasibility Stud"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Long COVID (LC) affects around two million people in the UK and over 65 million people globally. Antiviral medications have shown positive effects in reducing the risk of progression to severe disease in high-risk patients during an acute SARS-CoV-2 infection and have improved outcomes in those living with LC. Research testing the feasibility and efficacy of antiviral medications is ongoing, and clinical trials should determine the use of Remdesivir and its impact on LC symptoms, patient-reported outcomes, quality of life and functional status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Seventy-two patients\u2009\u2265\u200918\u00a0years of age who have a confirmed LC diagnosis will be recruited across two sites to trial Remdesivir\n                      <jats:sub>TM<\/jats:sub>\n                      treatment delivered via intravenous infusion over 5\u00a0days. This feasibility study will provide high-quality data to estimate screening rates, recruitment through different pathways, retention and treatment adherence. The study will also determine the definitive trial\u2019s most clinically relevant primary outcome. After a detailed screening process, patient-reported and clinical outcome measures (including EQ-5D-5L, Symptom Burden Questionnaire\u2122 for LC (SBQ\u2122), cardiopulmonary exercise tests (CPET), lung function, biomarkers and inflammatory profiles) will be collected to determine symptoms and impact of their condition, which will be repeated post-treatment. A subset of 20 participants will undergo whole-body\u00a0parametric Fluorodeoxyglucose (FDG) PET\/CT\u00a0to measure multi-organ metabolic activity. Due to the established physical, cognitive and clinical impairment impacts of LC, patient involvement has been extensively embedded within the design and implementation of all study processes to increase patient safety and delivery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study will provide data on the feasibility of a trial of 5-day intravenous treatment with Remdesivir for patients with LC. The treatment is already effective in the treatment of patients with acute severe cases of SARS-CoV-2. Remdesivir has an established safety profile and carries no higher risk to patients than standard medical care. The findings will inform the design of a future definitive study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>ISRCTN Number: 72940450.<\/jats:p>\n                    <jats:p>Date registered: 07\/06\/2024.<\/jats:p>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN72940450\" ext-link-type=\"uri\">https:\/\/www.isrctn.com\/ISRCTN72940450<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                    <jats:p>ClinicalTrials.gov Number: NCT05911906.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40814-026-01823-9","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:27:22Z","timestamp":1777598842000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An open-label, clinical feasibility study of the efficacy of Remdesivir for Long-COVID"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8288-0261","authenticated-orcid":false,"given":"Helen","family":"Neilens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Allgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayle-Anne","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Chynoweth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paigan J.","family":"Aspinall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Hambly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Skipper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Bewick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hairil Abdul","family":"Razak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Strain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Knapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Faghy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"1823_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133\u201346. https:\/\/doi.org\/10.1038\/s41579-022-00846-2.","journal-title":"Nat Rev Microbiol"},{"key":"1823_CR2","unstructured":"World Health Organisation. Coronavirus disease (COVID-19): Post COVID-19 condition. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/coronavirus-disease-(covid-19)-post-covid-19-condition. Accessed 13 Apr 2022"},{"key":"1823_CR3","unstructured":"Proal AD, Aleman S, Bomsel M, et al. Targeting the SARS-CoV-2 reservoir in long COVID. Lancet Infect Dis. Published online 2025. https:\/\/www.thelancet.com\/journals\/laninf\/article\/PIIS1473-3099(24)00769-2\/abstract. Accessed 13 Feb 2025."},{"issue":"3","key":"1823_CR4","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1093\/cid\/ciac722","volume":"76","author":"Z Swank","year":"2023","unstructured":"Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating severe acute respiratory syndrome coronavirus 2 Spike is associated with post-acute coronavirus disease 2019 sequelae. Clin Infect Dis. 2023;76(3):e487\u201390. https:\/\/doi.org\/10.1093\/cid\/ciac722.","journal-title":"Clin Infect Dis"},{"issue":"7941","key":"1823_CR5","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/s41586-022-05542-y","volume":"612","author":"SR Stein","year":"2022","unstructured":"Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612(7941):758\u201363. https:\/\/doi.org\/10.1038\/s41586-022-05542-y.","journal-title":"Nature"},{"issue":"2","key":"1823_CR6","doi-asserted-by":"publisher","first-page":"e28568","DOI":"10.1002\/jmv.28568","volume":"95","author":"V Craddock","year":"2023","unstructured":"Craddock V, Mahajan A, Spikes L, et al. Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19. J Med Virol. 2023;95(2):e28568. https:\/\/doi.org\/10.1002\/jmv.28568.","journal-title":"J Med Virol"},{"key":"1823_CR7","doi-asserted-by":"crossref","unstructured":"Peluso MJ, Swank ZN, Goldberg SA, et al. Plasma-based antigen persistence in the post-acute phase of SARS-CoV-2 infection. medRxiv. Published online 2023:2023\u201310.","DOI":"10.1101\/2023.10.24.23297114"},{"issue":"9","key":"1823_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/PHM.0000000000001505","volume":"99","author":"TJ Wang","year":"2020","unstructured":"Wang TJ, Chau B, Lui M, Lam GT, Lin N, Humbert S. Physical medicine and rehabilitation and pulmonary rehabilitation for COVID-19. Am J Phys Med Rehabil. 2020;99(9):769\u201374.","journal-title":"Am J Phys Med Rehabil"},{"key":"1823_CR9","doi-asserted-by":"crossref","unstructured":"Grundeis F, Ansems K, Dahms K, et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2023;(1). https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD014962.pub2\/abstract\n. Accessed 5 Oct 2023.","DOI":"10.1002\/14651858.CD014962.pub2"},{"issue":"6","key":"1823_CR10","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post\u2013COVID-19 condition. JAMA Intern Med. 2023;183(6):554\u201364.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"1823_CR11","first-page":"135","volume":"65","author":"JE Freal","year":"1984","unstructured":"Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch Phys Med Rehabil. 1984;65(3):135\u20138.","journal-title":"Arch Phys Med Rehabil"},{"issue":"3","key":"1823_CR12","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0022-3999(94)00125-O","volume":"39","author":"EMA Smets","year":"1995","unstructured":"Smets EMA, Garssen B, Bonke B, De Haes J. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39(3):315\u201325.","journal-title":"J Psychosom Res"},{"key":"1823_CR13","doi-asserted-by":"crossref","unstructured":"Klok FA, Boon GJ, Barco S, et al. The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19. Eur Respir J. 2020;56(1). https:\/\/erj.ersjournals.com\/content\/56\/1\/2001494.short. Accessed 31 Oct 2023.","DOI":"10.1183\/13993003.01494-2020"},{"key":"1823_CR14","doi-asserted-by":"crossref","unstructured":"Hughes SE, Haroon S, Subramanian A, et al. Development and validation of the symptom burden questionnaire for long covid (SBQ-LC): Rasch analysis. Bmj. 2022;377. https:\/\/www.bmj.com\/content\/377\/bmj-2022-070230.abstract. Accessed 20 May 2025.","DOI":"10.1136\/bmj-2022-070230"},{"issue":"3","key":"1823_CR15","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/occmed\/kqm162","volume":"58","author":"C Stenton","year":"2008","unstructured":"Stenton C. The MRC breathlessness scale. Occup Med. 2008;58(3):226\u20137.","journal-title":"Occup Med"},{"key":"1823_CR16","unstructured":"Sullivan MJ, Edgley K, Dehoux E. A survey of multiple sclerosis: I. Perceived cognitive problems and compensatory strategy use. Can J Rehabil. Published online 1990. https:\/\/psycnet.apa.org\/record\/1991-21978-001. Accessed 20 May 2025."},{"issue":"10","key":"1823_CR17","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, L\u00f6we B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092\u20137.","journal-title":"Arch Intern Med"},{"issue":"3","key":"1823_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1348\/1359107041557048","volume":"9","author":"J De Vries","year":"2004","unstructured":"De Vries J, Michielsen H, Van Heck GL, Drent M. Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS). Br J Health Psychol. 2004;9(3):279\u201391. https:\/\/doi.org\/10.1348\/1359107041557048.","journal-title":"Br J Health Psychol"},{"issue":"2","key":"1823_CR19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.5603\/ARM.a2021.0002","volume":"89","author":"HJ Pick","year":"2021","unstructured":"Pick HJ, Faghy MA, Creswell G, et al. The feasibility and tolerability of using inspiratory muscle training with adults discharged from the hospital with community-acquired pneumonia. Adv Respir Med. 2021;89(2):216\u201320.","journal-title":"Adv Respir Med"},{"key":"1823_CR20","volume-title":"Standardisation of Lung Function Testing: Helpful Guidance from the ATS\/ERS Task Force","author":"G Laszlo","year":"2006","unstructured":"Laszlo G. Standardisation of Lung Function Testing: Helpful Guidance from the ATS\/ERS Task Force. BMJ Publishing Group Ltd; 2006."},{"key":"1823_CR21","unstructured":"Thomas C, Kudiersky N, Ansdell P, et al. Submaximal 2-day cardiopulmonary exercise testing to assess exercise capacity and post-exertional symptom exacerbation in people with Long COVID. Published online In Press."},{"issue":"11","key":"1823_CR22","doi-asserted-by":"publisher","first-page":"e012843","DOI":"10.1136\/bmjopen-2016-012843","volume":"6","author":"G McGregor","year":"2016","unstructured":"McGregor G, Nichols S, Hamborg T, et al. High-intensity interval training versus moderate-intensity steady-state training in UK cardiac rehabilitation programmes (HIIT or MISS UK): study protocol for a multicentre randomised controlled trial and economic evaluation. BMJ Open. 2016;6(11):e012843.","journal-title":"BMJ Open"},{"key":"1823_CR23","doi-asserted-by":"publisher","unstructured":"van der Togt V, Rossman JS. Hypothesis: inflammatory acid-base disruption underpins Long Covid. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1150105","DOI":"10.3389\/fimmu.2023.1150105"},{"key":"1823_CR24","unstructured":"Sport and Exercise Physiology Testing Guidelines: Volume II - Exercise and Clinical Testing: The British Association of Sport and Exercise Sciences Guide. Routledge & CRC Press. https:\/\/www.routledge.com\/Sport-and-Exercise-Physiology-Testing-Guidelines-Volume-II---Exercise-and-Clinical-Testing-The-British-Association-of-Sport-and-Exercise-Sci\/Davison-Smith-Hopker-Price-Hettinga-Tew-Bottoms\/p\/book\/9780367489847. Accessed 5 Sep 2024"},{"key":"1823_CR25","unstructured":"ACSM\u2019s Guidelines for Exercise Testing and Prescription. https:\/\/www.acsm.org\/education-resources\/books\/guidelines-exercise-testing-prescription. Accessed 5 Sep 2024."},{"issue":"24","key":"1823_CR26","doi-asserted-by":"publisher","first-page":"e653","DOI":"10.1161\/CIR.0000000000000461","volume":"134","author":"R Ross","year":"2016","unstructured":"Ross R, Blair SN, Arena R, et al. Importance of assessing cardiorespiratory fitness in clinical practice: a case for fitness as a clinical vital sign: a scientific statement from the American Heart Association. Circulation. 2016;134(24):e653\u201399.","journal-title":"Circulation"},{"issue":"1","key":"1823_CR27","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40814-021-00770-x","volume":"7","author":"M Lewis","year":"2021","unstructured":"Lewis M, Bromley K, Sutton CJ, McCray G, Myers HL, Lancaster GA. Determining sample size for progression criteria for pragmatic pilot RCTs: the hypothesis test strikes back! Pilot Feasibility Stud. 2021;7(1):40. https:\/\/doi.org\/10.1186\/s40814-021-00770-x.","journal-title":"Pilot Feasibility Stud"},{"key":"1823_CR28","doi-asserted-by":"crossref","unstructured":"Eldridge SM, Chan CL, Campbell MJ, et al. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. bmj. 2016;355. https:\/\/www.bmj.com\/content\/355\/bmj.i5239.abstract. Accessed 17 Apr 2025.","DOI":"10.1136\/bmj.i5239"},{"issue":"2","key":"1823_CR29","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1823_CR30","unstructured":"R Core Team R. R: A language and environment for statistical computing. Published online 2013. https:\/\/apps.dtic.mil\/sti\/citations\/AD1039033. Accessed 20 May 2025."}],"container-title":["Pilot and Feasibility Studies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40814-026-01823-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40814-026-01823-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:55:43Z","timestamp":1781826943000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40814-026-01823-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1186\/s40814-026-01823-9","relation":{},"ISSN":["2055-5784"],"issn-type":[{"value":"2055-5784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"25 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval has been obtained from the UK Health Research Authority (HRA), the Medicines and Healthcare products Regulatory Agency (MHRA) and the South Central \u2013 Oxford B Research Ethics Committee (REC). All patients have provided informed consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. There is no patient data or identifiers in this publication; therefore, consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}